The Latest Psoriasis Journal Articles

Keep up to date with the latest in psoriasis. Check out the latest psoriasis articles from leading medical journals in a single view, helping you discover relevant articles quickly and easily.

• Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a scoping review of dermatology clinical practice guidelines.3rd May 2021
  Clinical practice guidelines (CPGs), statements that include recommendations intended to optimise patient care, play a critical role in standardising and improving treatment outcomes based on best evidence. It is currently unclear how many CPGs are available globally to assist clinicians in the management of patients with skin disease.Our aim was to search for and identify […]
• The incidence of psoriasis in Chile: an analysis of the national Waiting List Repository.29th April 2021
  Psoriasis is a serious, chronic non-communicable disease. However, the fundamental measure of disease occurrence, incidence, has been scarcely reported globally. There are no previous studies of psoriasis incidence in Latin America.This study aims to estimate incidence rates of psoriasis in Chile during 2016 and 2017 using an administrative database, the Waiting List Repository.We examined referrals […]
• Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis: Results from the EXCEED, a randomised, double-blind head-to-head monotherapy study.29th April 2021
  Secukinumab (an interleukin [IL]-17A inhibitor) has demonstrated significantly higher efficacy vs. etanercept (a tumour necrosis factor inhibitor) and ustekinumab (an IL-12/23 inhibitor) in patients with moderate to severe plaque psoriasis.To report 52-week results from a pre-specified analysis of patients with active psoriatic arthritis (PsA) having concomitant moderate to severe plaque psoriasis from head-to-head EXCEED monotherapy […]
• A review of Nigella sativa plant-based therapy in dermatology.26th April 2021
  Nigella sativa (N. sativa) is a widely used medicinal herb with a rich cultural and religious history in Unani, Ayurveda, Chinese, and Arabic medicine. N. sativa contains many natural bioactive agents including alkaloids, saponins, alpha-hederin, and thymoquinone that contribute to its broad range of benefits as a diuretic, bronchodilator, antihypertensive, antidiabetic, and analgesic. In addition, […]
• Drop in biological initiation for patients with psoriasis during the COVID-pandemic.24th April 2021
  Biologics have become the backbone of chronic inflammatory diseases treatment, including psoriasis. Post-approval studies allowed to better understand their safety profile demonstrating a favorable risk-benefit ratio despite an increased risk of infection, and especially an increased risk of bacterial infection with anti-TNF agents. View the full article @ The British journal of dermatology Get PDF […]
• Bimekizumab versus Adalimumab in Plaque Psoriasis.23rd April 2021
  Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with the tumor necrosis factor inhibitor adalimumab in patients with moderate-to-severe plaque psoriasis have not been extensively examined.We randomly assigned patients with moderate-to-severe plaque psoriasis in a 1:1:1 ratio to receive subcutaneous bimekizumab at a […]
• Bimekizumab versus Secukinumab in Plaque Psoriasis.23rd April 2021
  Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with secukinumab, which selectively inhibits interleukin-17A alone, in patients with moderate-to-severe plaque psoriasis have not been extensively examined.In this phase 3b trial, we randomly assigned patients with moderate-to-severe plaque psoriasis, in a 1:1 ratio, […]
• Association of gender and systemic therapy treatment outcomes in psoriasis: a two-country, multi-centre, prospective, non-interventional registry study.10th April 2021
  Psoriasis is a stigmatizing disease that often affects female patients more negatively than male patients. Very little systematic data on the treatment responses related to gender exists.This two-country, multi-centre, prospective, non-interventional registry study aimed to evaluate potential gender differences with respect to systemic anti-psoriatic treatment.Data of patients with moderate to severe psoriasis participating in the […]
• Defining Trajectories of Response in Psoriasis Patients Treated with Biologic Therapies.8th April 2021
  The effectiveness and cost-effectiveness of biologic therapies for psoriasis are significantly compromised by variable treatment responses. Thus, more precise management of psoriasis is needed.We aim to identify subgroups of psoriasis patients treated with biologic therapies, based on changes in their disease activity over time, that may better inform patient management.Here we apply latent class mixed […]
• The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and post-marketing surveillance data.8th April 2021
  Data on the use of biologic therapy and malignancy risk are inconsistent due to limited long-term robust studies.To assess the malignancy risk in secukinumab-treated psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients.This integrated safety analysis from both the secukinumab clinical trial program and post-marketing safety surveillance data included any patient receiving at least one […]
• Is apremilast for psoriasis as effective and safe as reported in clinical trials? Five-year experience from a Greek tertiary hospital.3rd April 2021
  Apremilast was approved as an effective and safe treatment for psoriasis, but clinical trial results may differ from real-life data. This retrospective cross-sectional study evaluated the long-term efficacy and safety of apremilast in a Greek cohort of adult psoriasis patients, who had received at least one dose of the drug between March 2016 and January […]
• Prevalence and incidence of palmoplantar pustulosis in Sweden: a population-based register study.1st April 2021
  Palmoplantaris pustulosis (PPP) is a chronic relapsing skin condition characterized by sterile pustules on the palm and soles. Population-based estimates of PPP incidence and prevalence are limited.To estimate the prevalence and incidence of PPP in the Swedish general population and to estimate the prevalence of psoriasis vulgaris among the PPP population.The Swedish National Patient Register, […]
• Signaling of multiple IL-17 family cytokines through IL-17RA drive psoriasis-related inflammatory pathways.1st April 2021
  The IL-23/IL-17 immune axis is of central importance in psoriasis. However, the impact of IL-17 family cytokines other than IL-17A in psoriasis has not been fully established.To elucidate the contribution of IL-17 family cytokines in psoriasis, we performed a comprehensive and systematic analysis of their expression, localization and functional activity.To address the expression and localization […]
• Inflammatory Skin Diseases and the Risk of Chronic Kidney Disease – Population-Based Case-control and Cohort analyses.17th March 2021
  Emerging evidence suggests an association between common inflammatory skin diseases and chronic kidney disease (CKD).To explore the association between CKD stages 3-5 and atopic eczema, psoriasis, rosacea, and hidradenitis suppurativa.We undertook two complementary analyses; a prevalent case-control and a cohort study using routinely collected primary care data (UK Clinical Practice Research Datalink [CPRD]). We matched […]
• Circulating long noncoding RNA growth arrest-specific transcript 5 as a diagnostic marker and indicator of degree of severity in plaque psoriasis.15th March 2021
  The current study aims at evaluating the role of circulating or cell-free long noncoding ribonucleic acid (lncRNA) growth arrest-specific 5 (GAS5) in plaque psoriasis and at investigating its relationship with the presented clinical data.This case-control study was conducted on 180 subjects, divided into two main categories as follows: 90 cases with plaque psoriasis and 90 […]
• Sexual function is adversely affected in the majority of men presenting with penile lichen sclerosus.13th March 2021
  Male genital lichen sclerosus (MGLS) is a chronic inflammatory condition which can present with a range of debilitating symptoms. Sexual dysfunction is reported by most women with lichen sclerosus but by relatively few men. This prospective study looked at 78 men with genital lichen sclerosus. Sexual difficulties were experienced by 64 (82%) patients with 54 […]
• Association of pediatric atopic dermatitis and psoriasis with school absenteeism and parental work absenteeism: a cross-sectional United States population-based study.5th March 2021
  The impact of childhood atopic dermatitis (AD) and psoriasis on school absenteeism are not fully elucidated.To determine the burden and predictors of chronic school absenteeism in children with AD and psoriasis.Data were analyzed from the 1999-2015 Medical Expenditure Panel Surveys, a cross-sectional, population-based study of US health status and function.Among 3132 and 200 children with […]
• Oral dimethyl fumarate induces changes within the peripheral neutrophil compartment of psoriasis patients that are linked with skin improvement.3rd March 2021
  Dimethyl fumarate (DMF) is a treatment for moderate-to-severe psoriasis and multiple sclerosis. DMF therapy typically improves skin inflammation within the first 3 months of treatment. DMF is a prodrug that generates the hydroxycarboxylic acid receptor 2 (HCA2) agonist, monomethyl fumarate (MMF). Despite widespread clinical use, DMF’s mechanism of action is not fully understood.We wished to […]
• Comparative Safety and Benefit-Risk Profile of Biologics and Oral Treatments for Moderate-to-Severe Plaque Psoriasis: a Network Meta-Analysis of Clinical Trial Data.25th February 2021
  The comparative safety and benefit-risk profiles of moderate-to-severe psoriasis treatments have not been well studied.To compare the short-term (12-16 weeks) and long-term (48-56 weeks) safety and benefit-risk profiles of moderate-to-severe psoriasis treatments.A systematic literature review of Phase II-IV randomized controlled trials (RCTs) of moderate-to-severe psoriasis treatments was conducted (cut-off: 07/01/2020). Any adverse events (AE), any […]
• Medical imaging examination in psoriasis and early psoriatic arthritis patients: an updated systematic review and meta-analysis.21st February 2021
  Psoriatic arthritis appears in one in four skin psoriasis patients. Early detection of the presence of joint involvement and early interception of its developments may minimize long-term functional disability, and the radiological methods may be a perfect choice. To summarize and compare different imaging methods for diagnosing early-stage psoriatic arthritis and determine the necessity of joint […]
• Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: a population-based study.19th February 2021
  Patients with psoriatic disease may be more susceptible to methotrexate hepatotoxicity than those with rheumatoid arthritis (RA) but direct evidence is lacking.To compare liver disease risk among patients with psoriasis (PsO), psoriatic arthritis (PsA), and RA receiving methotrexate METHODS: In a population-based cohort study, Danish individuals with PsO, PsA, or RA receiving methotrexate during 1997-2015 […]
• Beclin1 in Psoriasis: An Immunohistochemical Study.6th January 2021
  Abnormal autophagy is now established to be associated with pathogenesis of some skin disorders. Beclin1 plays a central role in the machinery of the autophagy.to assess the expression of “Beclin1” in psoriasis through its immunohistochemical study in lesional and perilesional skin in psoriasis cases.This case-control study was carried out on a total number of 40 […]
• Metabolic Syndrome and its Factors are Associated with Non-Calcified Coronary Plaque Burden in Psoriasis: An Observational Cohort Study.31st December 2020
  Psoriasis is associated with a heightened risk of cardiovascular disease (CVD) and higher prevalence of metabolic syndrome (MetSyn) and its individual components.Investigate the impact of MetSyn and its components on early coronary artery disease assessed as non-calcified coronary burden (NCB) by coronary computed tomography angiography (CCTA) in psoriasis.This cross-sectional study consisted of 260 participants with […]
• Efficacy and safety of fumaric acid esters in young patients aged 10 to 17 years with moderate-to-severe plaque psoriasis – A randomised, double-blinded, placebo-controlled trial.17th December 2020
  Apart from three biologics, no systemic drugs are approved in Europe for children with moderate-to-severe psoriasis. Retrospective observational studies showed promising results for fumaric acid esters (FAE) in this setting.To show superiority of FAE over placebo in terms of treatment response after 20 weeks in children and adolescents aged 10-17 years.In a multicentre, randomised, double-blind, […]
• Infantile infection and antibiotic exposure in association with pediatric psoriasis development: a nationwide nested case-control study.15th December 2020
  Microbiol dysbiosis and antibiotic exposure have been implicated in the pathogenesis of pediatric inflammatory diseases.To investigate the impacts of infantile infection and antibiotic exposure on pediatric psoriasis development METHODS: This is a nationwide nested case control study. From the National Health Insurance Research Database of Taiwan, a total of 1,527 patients with pediatric psoriasis were […]
• Why don’t people with psoriasis take enough exercise?14th December 2020
  Psoriasis is a chronic skin condition which causes red, scaly patches and affects around 2% of the population. People with psoriasis are more likely than others to suffer cardiovascular disease (e.g. heart attack or stroke). It is well known that regular physical exercise reduces the risk of cardiovascular disease, but, worryingly, people with psoriasis take […]
• Immune checkpoint-mediated psoriasis: a multicentric European study of 115 patients from European Network for Cutaneous ADverse Event to Oncologic drugs (ENCADO) group.6th December 2020
  Immune checkpoint inhibitors (ICIs)-mediated psoriasis poses significant diagnostic and therapeutic challenges.To report data on ICI-mediated psoriasis, emerging from the largest so far cohort and to propose a step-by-step management algorithm.The medical records of all patients with ICI-mediated psoriasis were retrospectively reviewed across nine institutions.We included a cohort of 115 individuals. Grade-1, 2 and 3 disease […]
• CCL20 in Psoriasis: A Potential Biomarker of Disease Severity, Inflammation, and Impaired Vascular Health.1st December 2020
  Psoriasis is associated with increased cardiovascular risk that is not captured by traditional pro-inflammatory biomarkers.To investigate the relationship between psoriasis area and severity index (PASI), circulating pro-inflammatory biomarkers, and vascular health in psoriasis.In psoriasis and age, sex-matched controls, 273 proteins were analyzed utilizing the OLINK platform, while vascular endothelial inflammation and health was measured via […]
• Biologic drug survival rates in the era of anti-Il-17 antibodies: a time period-adjusted registry analysis.1st December 2020
  Drug survival rates reflect efficacy and safety and may be influenced by the availability of alternative treatment options. Little is known about time-dependent drug survival in psoriasis and the effect of increasing numbers of biologic treatment options.To determine whether drug survival is influenced by the availability of treatment options and by factors such as gender, […]
• Incidence of psoriasis among adults in the United States: A sex- and age-adjusted population analysis.30th November 2020
  Information on recent trends in overall and subgroup incidences in psoriasis is limited.To estimate current incidence of psoriasis in the U.S., compare incidences among demographic subgroups, and evaluate recent disease trends.Retrospective cohort analysis of psoriasis patients identified using electronic health records between 2014 and 2018.Incidence rate in the overall population (n=2,152,192) was 63.8 (95% CI […]
• Long-term efficacy and safety of ixekizumab: 5-year analysis of the UNCOVER-3 randomized controlled trial.30th November 2020
  To report efficacy and safety of the approved IXE dose over 5 years from UNCOVER-3. (NCT01646177).Patients (N=1346) were randomized 1:2:2:2 to receive subcutaneous injections of placebo, etanercept 50 mg twice weekly, IXE 80 mg every 2 weeks (Q2W) or every 4 weeks (Q4W) following an initial dose of IXE 160 mg. At Week 12, patients […]
• Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic AhR modulating agent (TAMA).6th November 2020
  Tapinarof, a novel, first-in-class small-molecule topical therapeutic aryl hydrocarbon receptor (AhR) modulating agent (TAMA), is in clinical development for the treatment of psoriasis and atopic dermatitis. The efficacy of tapinarof in psoriasis is attributed to its specific binding and activation of AhR, a ligand-dependent transcription factor, leading to the downregulation of pro-inflammatory cytokines, including interleukin-17, […]
• Quality of life, treatment goals, preferences and satisfaction in older adults with psoriasis: a patient survey comparing age groups.6th November 2020
  Psoriasis management in the rapidly expanding geriatric population can be complex due to frailty, comorbidities, comedication and limited available data on treating older psoriasis patients.1 Previous studies reported comparable disease severity in patients ≥65 years old (≥65yo) and patients <65yo,2-4 although prescribed antipsoriatic therapies differed between age groups.2,3,5 This might be due to comorbidities and […]
• Risk of Skin Disorders in Patients with Celiac Disease: A Population-Based Cohort Study.4th November 2020
  Although dermatitis herpetiformis is closely associated with celiac disease (CD), data on the relationship between CD and other dermatologic disorders have been mixed. We aimed to quantify the risk of skin disorders in patients after CD diagnosis in a population-based setting.Using data from all 28 pathology departments in Sweden 1969-2016, we identified patients with CD. […]
• Trends in Mortality and Cause-specific Mortality among patients with Psoriasis and Psoriatic Arthritis in Ontario, Canada.23rd October 2020
  There is limited information about mortality rates among patients with psoriasis and psoriatic arthritis (PsA) in North America and their change over the past two decades.To compare all-cause and cause-specific mortality rates in psoriatic patients to the general population in Ontario, Canada from 1996 to 2016.We conducted a population-based, retrospective cohort study of adult residents […]
• “Fake news” in dermatology. Results from an observational, cross-sectional study.23rd October 2020
  Social networks have become a means for disseminating information on health-related matters.Describe the characteristics and analyze the accuracy of the dermatology content that is most often shared on the most popular social networks.The content most often shared on social networks (Facebook, Pinterest, Twitter, and Reddit) between March 2019 and March 2020 was analyzed using the […]
• Association of Psoriasis with Colorectal Cancer: A Systematic Review and Meta-Analysis.4th October 2020
  The relation between psoriasis and colorectal cancer (CRC) was largely unclear.To investigate the association of psoriasis with CRC.A systematic review and meta-analysis of observational studies that examined the association of psoriasis with CRC was performed. We searched MEDLINE and Embase on March 24, 2020 for relevant studies. The Newcastle-Ottawa scale was used to evaluate the […]
• QuantiFERON TB-gold conversion rate among psoriasis patients under biologics: a 9-year retrospective study.29th September 2020
  Tuberculosis (TB) screening is mandatory for psoriasis biologic treatment. However, evidences regarding TB screening results during biologic treatment are conflicting.The aim of this study is to evaluate the rate of QuantiFERON TB Gold test (QFT) conversion in psoriasis patients during biologics over time.A 9-year single center retrospective study was performed in order to evaluate the […]
• Applications and Future Directions for Optical Coherence Tomography in Dermatology.24th September 2020
  Optical coherence tomography (OCT) is a non-invasive optical imaging method that can generate high-resolution en-face and cross-sectional images of the skin in vivo to a maximum depth of 2mm. Whilst OCT holds considerable potential for non-invasive diagnosis and disease monitoring, it is poorly understood by many dermatologists. Here, we aim to equip the practicing dermatologist […]
• Interventions for chronic palmoplantar pustulosis: abridged Cochrane systematic review and GRADE assessments.22nd September 2020
  Palmoplantar pustulosis (PPP) is a chronic inflammatory disease in which sterile and relapsing pustules appear on the palms and soles.To assess the effects of interventions for chronic PPP to induce and maintain complete remission.We searched for randomised controlled trials (RCTs), including people with PPP or chronic palmoplantar pustular psoriasis, in Cochrane Skin Specialised Register, CENTRAL, […]
• Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).22nd September 2020
  Data for the effect of metabolic syndrome (MetS) on efficacy and safety of biologic agents for psoriasis treatment are limited.To evaluate long-term tildrakizumab efficacy, drug survival, and safety in patients with psoriasis by baseline MetS status.Post hoc analyses of up to 3 years of efficacy data and 5 years of safety data from the phase […]
• Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).20th September 2020
  Topical psoriasis treatment relies on a reactive, rather than long-term proactive, approach to disease relapse.Assess long-term efficacy and safety of proactive psoriasis management with twice-weekly calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam.Phase III trial (NCT02899962) included a 4-week open-label lead-in phase (Cal/BD foam once-daily) and 52-week, randomized, double-blind, maintenance phase. 545 patients achieved treatment success PGA […]
• Clinical Presentation and Management of Atypical and Recalcitrant Acute Generalized Exanthematous Pustulosis (AGEP).14th September 2020
  Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction (SCAR) characterized by sterile non-follicular pustules on an erythematous base that form rapidly after drug exposure. AGEP is mediated by numerous cytokines produced by drug specific T-cells that mediate neutrophilic intracorneal, subcorneal, and/or intraepidermal pustule development. Though genetic susceptibility is not fully understood, individuals […]
• Clinical Presentation and Management of Atypical and Recalcitrant Acute Generalized Exanthematous Pustulosis (AGEP).14th September 2020
  Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction (SCAR) characterized by sterile non-follicular pustules on an erythematous base that form rapidly after drug exposure. AGEP is mediated by numerous cytokines produced by drug specific T-cells that mediate neutrophilic intracorneal, subcorneal, and/or intraepidermal pustule development. Though genetic susceptibility is not fully understood, individuals […]
• The epidemiology of hidradenitis suppurativa.4th September 2020
  Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease defined clinically by multiple, painful inflammatory lesions occurring predominantly in flexural sites. Onset is typically soon after puberty; however, it remains unknown whether the menopause induces remission. In North American and European patients with HS the female-to-male ratio is approximately 3 : 1 but the ratio is 1 : 2 […]
• A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial.4th September 2020
  Significantly more patients with moderate-to-severe plaque psoriasis treated with the interleukin (IL)-17A inhibitor ixekizumab vs. the IL-23p19 inhibitor guselkumab in the IXORA-R head-to-head trial achieved 100% improvement in Psoriasis Area and Severity Index (PASI 100) at Week 12.To compare skin and nail clearance and patient-reported outcomes for ixekizumab vs. guselkumab, up to Week 24.IXORA-R enrolled […]
• Assessing work-related productivity loss and indirect costs of psoriasis across six countries.4th September 2020
  Psoriasis is a skin disease that can negatively impact on patients’ psychosocial well-being. It affects millions of people worldwide. The overall economic burden (meaning the cost to the economy) of psoriasis is severe; however, no study has fully assessed it due to a lack of comparable data from different countries. This study looked at work […]
• Modifiable Lifestyle and Environmental Factors Associated with Onset of Psoriatic Arthritis in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.23rd August 2020
  Psoriatic arthritis (PsA) is a progressive joint disease associated with psoriasis.To investigate the association of modifiable lifestyle and environmental factors with PsA risk among people with psoriasis.We conducted a systematical search of PubMed, EMBASE and Cochrane Library up to 2 May 2020 for observational studies reporting lifestyle or environmental factors for PsA onset in psoriasis […]
• Comorbidities in patients with palmoplantar plaque psoriasis.20th August 2020
  Psoriasis has been shown to be associated with several comorbidities. Whether the palmoplantar subtype of plaque psoriasis carries similar risks for comorbidities as generalized plaque psoriasis remains to be defined.To examine the association between palmoplantar plaque psoriasis and comorbidities known to be associated with generalized plaque psoriasis.We retrospectively compared the prevalence of comorbidities previously found to be […]
• Reduced Risk of Mortality Associated With Systemic Psoriasis Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A Nested Case-Control Analysis.18th August 2020
  The effects of systemic therapy on mortality risk among patients with psoriasis are not fully understood.To evaluate the impact of systemic treatment on mortality risk in patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).Nested case-control analyses were performed to estimate mortality risk. Cases were defined as patients who died while participating in PSOLAR. […]
• The association of psoriasis and hypertension: focusing on anti-inflammatory therapies and immunological mechanisms.14th August 2020
  Psoriasis is a chronic skin disease characterized by recurrent inflammation, and is increasingly being recognized as a systemic inflammatory disorder, which is associated with cardiovascular events, metabolic syndrome, diabetes, obesity and hypertension. Recent findings have suggested a greater risk of hypertension, particularly difficult-to-control hypertension, in patients with severe psoriasis. Additionally, abnormal activation of immune cells […]
• A phase I, randomized, double-blind study to assess the safety, tolerability, and efficacy of the topical RORC2 inverse agonist PF-06763809 in participants with mild-to-moderate plaque psoriasis.7th August 2020
  The transcription factor retinoic acid-related orphan receptor 2 (RORC2/RORγT) mediates interleukin (IL)-17A and IL-17F expression. IL-17A plays a central role in the pathogenesis of several inflammatory disorders, including psoriasis. The RORC2 inhibitor PF-06763809 has been hypothesized to inhibit IL-17A production in T-helper 17 (Th17) cells, thereby reducing psoriasis symptoms.To assess the safety, tolerability, and effect […]
• Research priorities and identification of a health-service delivery model for psoriasis from the UK Psoriasis Priority Setting Partnership.5th August 2020
  Psoriasis impacts the health and psychosocial functioning of patients, conferring a significant economic burden on healthcare systems. There remain unmet needs in psoriasis care, which if addressed by research, could improve clinical outcomes.Between July 2017 and November 2018 we conducted a Priority Setting Partnership for psoriasis (PsPSP). We invited those with lived-experience of psoriasis and […]
• Axial psoriatic arthritis: An update for dermatologists.5th August 2020
  Psoriasis is a chronic, immune-mediated, systemic, inflammatory disorder characterized by skin plaques and, often, nail disease and arthritis that contribute to reduced quality of life. Psoriatic arthritis-a heterogeneous, inflammatory, musculoskeletal disease that can cause permanent damage to both peripheral and axial joints-is the most common comorbidity of psoriasis. Axial disease occurs in 25% to 70% […]
• fJoint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.2nd August 2020
  Psoriasis is a chronic, inflammatory, multisystem disease which affects up to 3.2% of the U.S population. This guideline addresses important clinical questions that arise in psoriasis management and care and provides recommendations based on the available evidence. The treatment of psoriasis with topical agents and with alternative medicine (AM) will be reviewed, emphasizing treatment recommendations […]
• Management of nail psoriasis.2nd August 2020
  Nail involvement is estimated to affect 80-90% of patients with psoriasis at some point in their lives and is often associated with severe disease. Patients with nail involvement experience pain, functional impairment and social stigma, with significant restriction of daily activities and quality of life. Nail psoriasis is also considered a risk factor for the […]
• Shades of grey: what is paediatric psoriasiform dermatitis and what does it have in common with childhood psoriasis?1st August 2020
  While the majority of children with a chronic itchy rash suffer from atopic dermatitis (AD) and other forms of dermatitis, psoriasis is in the differential diagnosis. Certain patterns such as guttate and napkin psoriasis are accepted as classic paediatric psoriasis (PP), however there are many patients who do not fit these classic forms of OO […]
• Inflammatory nail conditions. Part 1: nail changes in psoriasis.31st July 2020
  Nail changes are visible in a variety of inflammatory dermatoses. The commonest dermatological condition with nail manifestations is chronic plaque psoriasis. This two-part article reviews the nail signs in psoriasis in Part 1, and the nail changes in cutaneous lichen planus and alopecia areata in Part 2. It provides a brief summary of the salient […]
• Efficacy of a second IL-17 inhibitor in patients with psoriasis: a systematic review and meta-analysis.31st July 2020
  Multiple biologics for psoriasis exist and interleukin (IL)-17 inhibitors are among those with best efficacy. However, switching treatment is often required at some point and intraclass switch of IL-17 inhibitors is not well investigated.To determine the efficacy of a second IL-17 inhibitor in patients with psoriasis.Two independent authors searched the databases PubMed and EMBASE for […]
• Trial of Roflumilast Cream for Chronic Plaque Psoriasis.16th July 2020
  Systemic oral phosphodiesterase type 4 (PDE-4) inhibitors have been effective in the treatment of psoriasis. Roflumilast cream contains a PDE-4 inhibitor that is being investigated for the topical treatment of psoriasis.In this phase 2b, double-blind trial, we randomly assigned adults with plaque psoriasis in a 1:1:1 ratio to use roflumilast 0.3% cream, roflumilast 0.15% cream, […]